Biopharma Daily Stock Updates - 01/08/21

$XBI $149.54 (+0.22%) 📈

COVID:

$BNTX (+7.15%) - An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

https://biontechse.gcs-web.com/news-releases/news-release-details/vitro-study-shows-pfizer-biontech-covid-19-vaccine-elicits

$MRNA (-2.03%) - United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna

https://investors.modernatx.com/news-releases/news-release-details/united-kingdom-medicines-and-healthcare-products-regulatory

PIPELINE:

$NLTX (-10.96%) - Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

http://investor.neoleukin.com/news-releases/news-release-details/neoleukin-therapeutics-receives-clinical-hold-letter-us-fda

$CMRX (+69.08) - Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage

$TCRR (+7.77%) - TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones

https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-2021-strategic-priorities-and

FINANCIAL:

ALDX (+21.72%) - Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $22

https://www.benzinga.com/news/20/08/17027493/citigroup-maintains-buy-on-aldeyra-therapeutics-lowers-price-target-to-22

$KMPH - KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market

https://investors.kempharm.com/news-releases/news-release-details/kempharm-announces-pricing-50-million-public-offering-common

$RGNX (-5.11%) - REGENXBIO Announces Pricing Of Public Offering Of Common Stock

http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-pricing-public-offering-common-stock-1